forms of tirzepatide | C225H348N48O68 | CID 156588324 Tirzepatide 30mg (t30) at 6136.00

Remember: Gradual weight loss is healthy weight loss

For additional perspective, heres a list of more studies that show the same: A potential link between liraglutide and thyroid cancer (along with pancreatic and gallbladder problems as well) (3) Study highlighting that liraglutide should not be used in people with a family history of medullary thyroid cancer (4) A study showing there is no increase in the risk of thyroid cancer (for additional perspective) (5) A meta-analysis showing that there is not enough evidence to suggest there is a link between thyroid cancer and GLP-1 agonists (6) Its worth pointing out that while there is still debate on this topic, the larger and bigger studies on this issue seem to support a connection between the two

Summary: Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 3 trials for obesity and type 2 diabetes but not yet approved by the MHRA, EMA, or FDA

This is similar to whats reported in FDA data, which shows the most common side effect, nausea, happens in 44% of people on Wegovy (compared to 16% of people on a placebo)